Kroger Health, the arm of grocer Kroger that runs pharmacies and clinics across the U.S., said on Friday it had revamped its ...
Analyzing Madrigal Pharmaceuticals' potential in the competitive NASH drug market and why it may be right for your portfolio.
Wegovy (semaglutide) is a prescription medication belonging to a group of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. It comes as a liquid solution that you self-inject just ...
In recent months, Eli Lilly has continued to delight investors with growth in its share price. Strong sales of the company's ...
For the past year and a half, Tandra Cooper Harris and her husband, Marcus, who both have diabetes, have struggled to fill ...
Learn about the side effects of Ozempic, Wegovy, Mounjaro and Zepbound, so you can weigh the risks versus benefits.
The Boston startup aims to provide an alternative obesity medicine to GLP-1 drugs, which the CEO said can come with "accessibility, cost, side effects and long-term maintenance" issues. A new ...
About one-third of U.S. employer health plans now cover GLP-1 drugs for both diabetes and weight management, according to a recent survey by the International Foundation of Employee Benefit Plans.
Taking a cutting-edge weight-loss drug could help extremely obese patients drop enough pounds to be eligible for bariatric surgery, a new study shows. Patients with extreme obesity -- a BMI of 70 ...
Boehringer Ingelheim today announced breakthrough results from a survodutide Phase II trial sub-analysis that demonstrate up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced ...
Obesity-Diabetes Drugs MarketAs per Future Market Insights’ latest industry analysis, the global obesity-diabetes drugs market was valued at around USD 54,452.0 million in 2023 and is anticipated to ...